![Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET](https://images.squarespace-cdn.com/content/v1/60b687d7c75a235d721c70d5/8c900f9c-6d15-45da-8393-2b43144a123d/Princess+Maxima.png)
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
Clinical [89Zr]Dinutuximab PET imaging to determine GD2 expression in neuroblastoma patients with PET
Dr. Max M. van Noesel, MD. PhD, MSc; – Princess Máxima Center, Utrecht, The Netherlands
Comprehensive molecular profiling of pediatric adrenal tumors
Comprehensive molecular profiling of pediatric adrenal tumors
Dr. Ronald de Krijger – Princess Máxima Center, Utrecht, The Netherlands
Pulmonary complications in children with solid tumors
Pulmonary complications in children with solid tumors
Dr. S.M.P.J. Prevaes; Dr. M. van Grotel – Princess Máxima Center, Utrecht, The Netherlands
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel